Search results
7 maj 2022 · A recent study has shown that complete clinical response to imiquimod is associated with coordinated influx of type 1 CD4 and CD8 T cells and CD14 inflammatory myeloid cells. 13 Patients without such a pre-existent and coordinated immune microenvironment might show resistance to therapy.
1 lis 2020 · In a 2016 Cochrane review of medical and surgical interventions for the treatment of VIN, Lawrie et al. [33] recommended surgical excision as second-line therapy for patients who fail to respond to medical treatment. That said, first-line surgical excision (preferably superficial vulvectomy) of small, well-circumscribed lesions would probably ...
Treatment options for VIN include surgical excision, laser ablation, and topical treatment with imiquimod. In many women, a combination of these modalities is used. Retrospective data have shown that approximately 30% of patients treated for VIN develop recurrent disease, irrespective of treatment modality used.
Treatment is recommended for all women with vulvar HSIL (VIN usual type). Because of the potential for occult invasion, wide local excision should be performed if cancer is suspected, even if biopsies show vulvar HSIL.
Objectives. Vulvar and vaginal intraepithelial neoplasias (VIN/VAIN) have an estimated incidence of 2.9 and 0.2–0.3 per 100,000 women, respectively. As they are considered pre-malignant, treatment with surgical resection or ablation is commonly performed to prevent progression to invasive disease.
The immunomodulator, imiquimod, has been proposed as a medical alternative to surgical treatments. We performed a systematic review and meta-analysis to determine the efficacy of topical imiquimod on the treatment of high-grade vulvar intraepithelial neoplasia (VIN 2 and VIN 3).
The most common treatment option has been surgery to remove the affected skin areas. Surgery, however, does not guarantee a cure, can be disfiguring, and may result in physical and psychological problems.
